ADRM1 Activators
ADRM1 activators are a class of compounds that target the Adhesion Regulating Molecule 1 (ADRM1), a protein that is implicated in a variety of cellular processes, including cell adhesion, protein degradation, and signal transduction. ADRM1 is known to function as a receptor for the 26S proteasome, a complex responsible for the ATP-dependent degradation of ubiquitinated proteins, and plays a role in the regulation of protein homeostasis within the cell.
The activation of ADRM1 by these specialized chemicals may be achieved through several potential mechanisms. Direct activators might bind to ADRM1 and induce a conformational change that increases its affinity for the proteasome or enhances its ability to recruit ubiquitinated proteins for degradation. This could result in a more efficient turnover of proteins and a more tightly regulated protein balance within the cell. Alternatively, indirect activators may work by increasing the expression levels of ADRM1, either through up-regulation of its gene transcription or through the stabilization of its mRNA. By increasing the amount of ADRM1 protein present in the cell, the capacity for proteasome-mediated degradation is augmented, indirectly enhancing the functional activity of ADRM1. In addition to these methods, activators could also modulate the activity of ADRM1 by influencing post-translational modifications that control its function. Modifications such as phosphorylation, ubiquitination, or sumoylation may alter the interaction between ADRM1 and other proteins, including those that are part of the ubiquitin-proteasome system, thereby affecting the efficiency of proteasomal degradation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that prevents the degradation of proteins via the proteasome. ADRM1 is a component of the proteasome, so inhibition of the proteasome by MG132 can lead to an increase in ADRM1 activity as it is less likely to be degraded. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is another proteasome inhibitor. Inhibition of the proteasome can enhance ADRM1 activity by preventing its degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of ADRM1, enhancing its functional activity within the proteasome. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Carfilzomib is a proteasome inhibitor that can enhance the activity of ADRM1 by preventing its degradation within the proteasome. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is a proteasome inhibitor that can enhance ADRM1 activity by preventing its degradation. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a proteasome inhibitor that can enhance the activity of ADRM1 by preventing its degradation within the proteasome. | ||||||
Oxaliplatin | 61825-94-3 | sc-202270 sc-202270A | 5 mg 25 mg | $110.00 $386.00 | 8 | |
Oxaliplatin is a platinum-based chemotherapeutic drug that can cause DNA damage leading to an increase in ubiquitinated proteins. This can enhance the activity of ADRM1, which is responsible for recognizing and binding to ubiquitinated proteins. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin is a platinum-based chemotherapeutic drug that can cause DNA damage leading to the increase in ubiquitinated proteins. ADRM1, being responsible for recognizing and binding to ubiquitinated proteins, can have its activity enhanced by such a change. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin is a chemotherapeutic drug that can induce DNA damage leading to the increase in ubiquitinated proteins. This can enhance the activity of ADRM1, which binds to these proteins. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide is a chemotherapeutic drug that can cause DNA damage leading to the increase in ubiquitinated proteins. This can enhance the activity of ADRM1, which binds to these proteins. | ||||||